Genetic and Environmental Susceptibility to Multiple Sclerosis
Main Article Content
Abstract
OBJECTIVE: To explore the nature and basis of environmental and genetic susceptibility to multiple sclerosis (MS).
BACKGROUND Susceptibility to multiple sclerosis (MS) is complex but clearly involves both environmental events and genetic factors. Certain epidemiological observations regarding MS (e.g., proportion of women among MS patients, population-prevalence of MS, impact of birth-month and migration patterns on the likelihood of MS, recurrence-risks for MS in siblings and twins, and time-dependent changes in MS-prevalence and the female to male sex-ratio) are well-established.
DESIGN/METHODS: We define the “genetically-susceptible” subset (G) to include everyone with any non-zero life-time chance of developing MS. Individuals who have no chance of developing MS, regardless of their environmental experiences, belong to the mutually exclusive “non-susceptible” subset (G–). We consider the implications that these well-established epidemiological observations have regarding the genetic and environmental basis of susceptibility to MS. In addition, we use the change in the female to male sex ratio, observed over a 35-year interval in Canada, to construct the response curves relating an increasing likelihood of MS to an increasing probability of a susceptible individual experiencing an environmental exposure sufficient to cause MS.
RESULTS: Environmental susceptibility to MS requires at least three different events – one occurring during the intrauterine or early post-natal period, another during childhood or adolescence, and a third (or more) many years later. Vitamin D deficiency and Epstein-Barr viral infections are likely involved. Moreover, we demonstrate that only a very small fraction of the general populations throughout Europe and North America is susceptible to MS. The vast majority of individuals in these populations has no chance whatsoever of developing MS, regardless of their environmental experiences. Even among carriers of the HLA-DRB1*15:01~HLA-DQB1*06:02~a1 haplotype, only a small minority can possibly be members the (G) subset. Also, despite the preponderance of women among MS patients, compared to men, women are less likely to be susceptible and have a higher environmental threshold for developing MS. Nevertheless, the penetrance of MS in susceptible women is substantially greater than it is in men. Moreover, MS-probability in susceptible individuals increases with an increasing likelihood of a sufficient environmental exposure, especially among women. However, these response-curves plateau at under 50% for women and at a significantly lower level for men.
CONCLUSIONS: The pathogenesis of MS requires both a genetic predisposition and a suitable environmental exposure. Nevertheless, genetic-susceptibility is rare in the population and requires specific combinations of non-additive genetic risk-factors. By contrast, a sufficient environmental exposure (however many events are involved, whenever these events need to act, and whatever these events might be) is common, currently occurring in, at least, 76% of susceptible individuals. In addition, the environmental response-curves (especially in men) plateau well below 50%, which indicates that disease pathogenesis is partially stochastic.
Article Details
How to Cite
GOODIN, Douglas S..
Genetic and Environmental Susceptibility to Multiple Sclerosis.
Medical Research Archives, [S.l.], v. 9, n. 6, june 2021.
ISSN 2375-1924.
Available at: <https://esmed.org/MRA/mra/article/view/2413>. Date accessed: 05 nov. 2024.
doi: https://doi.org/10.18103/mra.v9i6.2413.
Section
Research Articles
The Medical Research Archives grants authors the right to publish and reproduce the unrevised contribution in whole or in part at any time and in any form for any scholarly non-commercial purpose with the condition that all publications of the contribution include a full citation to the journal as published by the Medical Research Archives.
References
1. Goodin DS. The epidemiology of multiple sclerosis: Insights to a causal cascade. Handb Clin Neurol. 2016;138:173-206.
2. Vost A, Wolochow D, Howell D. Incidence of infarcts of the brain in heart diseases. J Path Bact. 1964;88:463-470.
3. Georgi VW. Multiple Sklerose: Patholiogisch-Anamtomische Befunde multiple Sklerose bei klinisch nicht diagniostizierte Krankbeiten. Schweiz Med Wochenschr. 1966;20:605-607.
4. Gilbert J, Sadler M. Unsuspected multiple sclerosis. Arch Neurol. 1983;40:533-536.
5. Engell T. A clinical patho-anatomical study of clinically silent multiple sclerosis. Acta Neurol Scand. 1989;79:428-430.
6. Gourraud PA, Harbo HF, Hauser SL, Baranzini SE. The genetics of multiple sclerosis: an up-to-date review. Immunol Rev. 2012;248:87–103.
7. Hofker MH, Fu J, Wijmenga C. The genome revolution and its role in understanding complex diseases. Biochim Biophys Acta. 2014;1842:1889-1895.
8. Goodin DS. The nature of genetic susceptibility to multiple sclerosis: Constraining the Possibilities. BMC Neurology. 2016;16:56.
9. Goodin DS. The Genetic and Environmental Bases of Complex Human-Disease: Extending the Utility of Twin-Studies. PLoS One. 2012;7(12): e47875.
10. Herrera BM, Cader MZ, Dyment DA, et al. Multiple sclerosis susceptibility and the X chromosome. Mult Scler. 2007;13:856–8.
11. Baranzini SE, Wang J, Gibson RA, et al. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet. 2009;18:767-778.
12. Sanna, S. Pitzalis M, Zoledziewska M, et al. Variants within the immunoregulatory CBLB gene are associated with multiple sclerosis. Nature Genet. 2010;42:495–497.
13. The International Multiple Sclerosis Genetics Consortium & the Wellcome Trust Case Control Consortium. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476:214-219.
14. International Multiple Sclerosis Genetics Consortium (IMSGC). Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis Nat Genet. 2014;45:1353-60.
15. International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map
implicates peripheral immune cells and microglia in susceptibility. Science. 2019;365 (6460). doi:10.1126/science.aav7188.
16. Dyment DA, Herrera BM, Cader Z, et al. Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance. Hum Mol Genet 2005;14:2019-2026.
17. Ramagopalan, SV, Anderson, C, Sadovnick, AD, Ebers, GC. Genomewide study of multiple sclerosis. N. Engl. J. Med. 2007;357, 2199–2200.
18. Link J, Kockum I, Lorentzen AR, et al. Importance of Human Leukocyte Antigen (HLA) Class I and II Alleles on the Risk of Multiple Sclerosis. PLoS One. 2012;7(5):e36779.
19. Patsopoulos NA, Barcellos LF, Hintzen RQ, et al. Fine-Mapping the Genetic Association of the Major Histocompatibility Complex in Multiple Sclerosis: HLA and Non-HLA Effects. PLoS Genet. 2014;9(11):e1003926.
20. Chao MJ, Barnardo MC, Lincoln MR, et al. HLA class I alleles tag HLA-DRB1*1501 haplotypes for differential risk in multiple sclerosis susceptibility. Proc Natl Acad Sci USA. 2008;105:13069-74.
21. Lincoln MR, Ramagopalan SV, Chao MJ, et al. Epistasis among HLA-DRB1, HLA-DQA1, and HLA-DQB1 loci determines multiple sclerosis susceptibility. Proc Natl Acad Sci USA. 2009;106:7542-7.
22. Sadovnick AD, Ebers GC, Dyment DA, et al., and the Canadian Collaborative Study Group. Evidence for genetic basis of multiple sclerosis. Lancet 1996;347:1728-1730.
23. Ebers GC, Yee IML, Sandovnick AD, Duquette P, and the Canadian Collaborative Study Group. Conjugal multiple sclerosis: Population-based prevalence and recurrence risks in offspring. Ann Neurol. 2000;48:927-931.
24. Willer CJ, Dyment DA, Risch NJ, Sadovnick AD, Ebers GC, the Canadian Collaborative Study Group. Twin concordance and sibling recurrence rates in multiple sclerosis. Proc Natl Acad Sci U S A. 2003;100:12877–82.
25. Dyment DA, Yee IML, Ebers GC, SadovnickAD, and the Canadian Collaborative Study Group. Multiple sclerosis in stepsiblings: Recurrence risk and ascertainment. J Neurol Neurosurg Psychiatry. 2006;77:258–259.
26. Orton SM, Herrera BM, Yee IM, et al., and the Canadian Collaborative Study Group. Sex ratio of multiple sclerosis in Canada: A longitudinal study. Lancet Neurol. 2006;5:932–6.
27. Sadovnick AD, Yee IML, Ebers GC, and the Canadian Collaborative Study Group. Multiple sclerosis and birth order: A longitudinal cohort study. Lancet Neurol. 2005;4:611–617.
28. Ebers GC, Sadovnick AD, Dyment DA, et al. Parent-of-origin effect in multiple sclerosis: observations in half-siblings. Lancet. 2004;363: 1773–1774.
29. Bager P, Nielsen NM, Bihrmann K, et al. Sibship characteristics and risk of multiple sclerosis: A nationwide cohort study in Denmark. Am J Epidemiol. 2006;163:1112–1117.
30. Kantarci OH, Barcellos LF, Atkinson EJ, et al. Men transmit MS more often to their children vs women: The Carter effect Neurology. 2006;67:305–310
31. Herrera BM, Ramagopalan SV, Orton S, et al. Parental transmission of MS in a population-based Canadian cohort. Neurology. 2007;69:1208–1212.
32. Islam T, Gauderman WJ, Cozen W, et al. Differential twin concordance for multiple sclerosis by latitude of birthplace Ann Neurol. 2006;60:56–64.
33. Robertson NP, Fraser M, Deans J, et al. Age-adjusted recurrence risks for relatives of patients with multiple sclerosis. Brain. 1996;119, 449-455.
34. Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359:1221-31.
35. Willer CJ, Dyment DA, Sadovnick AD, et al. Timing of birth and risk of multiple sclerosis: population based study. Br Med J. 2005;330:120-124.
36. Templer DI, Trent NH, Spencer DA, et al. Season of birth in multiple sclerosis. Acta Neurol Scand. 1992;85:107-109.
37. Staples J, Ponsonby AL, Lim L. Low maternal exposure to ultraviolet radiation in pregnancy, month of birth and risk of multiple sclerosis in offspring: a longitudinal analysis. Br Med J. 2010;340:c1640.
38. Torkildsen Ø, Aarseth J, Benjaminsen E, et al. Month of birth and risk of multiple sclerosis: confounding and adjustments. Ann Clin Transl Neurol. 2014;1:141–144.
39. Pantavou KG, Bagos PG. Season of birth and multiple sclerosis: a systematic review and multivariate meta‑analysis J Neurol. 2020;267:2815–2822.
40. Fiddes B, Wason J, Kemppinen A, et al. Confounding underlies the apparent month of birth effect in multiple sclerosis. Ann Neurol. 2013;73:714-270.
41. Fiddes B, Wason J, Sawcer S. Confounding in association studies: month of birth and multiple sclerosis J Neurol. 2014;261:1851-1856.
42. Dean G, Kurtzke JF. On the risk of multiple sclerosis according to age at immigration to South Africa. Br Med J. 1971;3:725-729.
43. Alter M, Kahana E, Loewenson R. Migration and risk of multiple sclerosis. Neurology. 1978;28:1089-1093.
44. Elian M, Nightingale S, Dean G. Multiple sclerosis among United Kingdom-born children of immigrants from the Indian subcontinent, Africa, and the West Indies. J Neurol Neurosurg Psychiatr. 1960;53:906-911.
45. Kahana E, Zilber N, Abramson JH, et al. Multiple sclerosis: Genetic versus environmental aetiology: Epidemiology in Israel updated. J Neurol. 1994;241:341-346.81
46. Cabre P. Signate A. Olindo S, et al. Role of return migration in the emergence of multiple sclerosis in the French West Indies Brain. 2005;128:2899–2910.
47. Compston A, Confavreux C, Lassmann H, et al., eds. McAlpine’s Multiple Sclerosis, 4th ed. London, UK: Churchill Livingston; 2006
48. Sumaya CV, Myers LW, Ellison GW. Epstein-Barr virus antibodies in multiple sclerosis. Arch Neurol. 1980;37:94–96.
49. Sumaya CV, Myers LW, Ellison GW, et al. Increased prevalence and titer of Epstein-Barr virus antibodies in patients with multiple sclerosis. Ann Neurol. 1985;17:371–377.
50. Ascherio A, Munger KL, Lennette ET, et al. Epstein-Barr virus antibodies and the risk of multiple sclerosis: A prospective study. Am Med Assoc J. 2001;286:3083-3088.
51. Goldacre MJ, Wotton CJ, Seagroatt V, et al. Multiple sclerosis after infectious mononucleosis: record linkage study. J Epidemiol Community Health. 2004;58:1032-1035.
52. Sundström P, Juto G, Wadell G, et al. An altered immune response to Epstein-Barr virus in multiple sclerosis: A prospective study. Neurology. 2004;62;2277-2282.
53. Haahr S, Plesner AM, Vestergaard BF, et al. A role of late Epstein-Barr virus infection in multiple sclerosis. Acta Neurol Scand. 2004;109: 270–275.
54. Ponsonby AL, van der Mei, Dwyer T, et al. Exposure to infant siblings during early life and risk of multiple sclerosis. Am Med Assoc J. 2005;293:463-9.
55. Farrell PJ. Role for HLA in susceptibility to infectious mononucleosis. J Clin Invest. 2007;117:2756-2758.
56. Nielsen TR, Rostgaard K, Nielsen NM, et al. Multiple sclerosis after infectious mononucleosis. Arch Neurol. 2007;64:72-75.
57. Serafini B, Roiscarelli B, Franciotta D, et al. Dysregulated Epstein-Barr virus infection in multiple sclerosis. J Exp Med. 2007;204:2899-2912.
58. Ascherio A, Munger KL. Epidemiology of Multiple Sclerosis: From Risk Factors to Prevention—An Update. Semin Neurol. 2016;36:103-114.
59. Abrahamyan S, Eberspächer B, Hoshi MM, et al. Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis J Neurol Neurosurg Psychiatry. 2020;91:681-686.
60. Henle W, Henle G, Andersson J, et al. Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection. Proc Natl Acad Sci (USA). 1987;84:570-574.
61. Holick MF. Vitamin D requirements for humans of all ages: new increased requirements for women and men 50 years and older. Osteoporos Int. 1998;8(Suppl 2):S24-29.
62. Hayes CE, Nashold FE Spach KM, et al. The immunological functions of the vitamin D endocrine system. Cell Molec Biol. 2003;49:277-300.
63. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev. 2005;26:662-687.
64. Lips P. Vitamin D physiology. Prog Biophys Molec Biol. 2006;92:4-8.
65. Sinclair H. Polyunsaturated fatty acids in multiple sclerosis. Br Med J. 1977;2:1217.
66. Koch-Henderson N. Multiple sclerosis in Scandinavia and Finland. Acta Neurol Scand. 1995;161:55-59.
67. Grønlie SA, Myrvoll E, Hansen G, et al. Multiple sclerosis in North Norway, and first appearance in an indigenous population. J Neurol. 2000;247:129–133.
68. Gillie O. A new government policy is needed for sunlight and vitamin D. Br J Dermatol. 2006;154:1052–1061.
69. Ramagopalan SV, Maugeri NJ, Handunnetthi L, et al. Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet. 2009;5(2):e1000369
70. Jablonski NG, Chaplin G. The evolution of human skin coloration. J Hum Evol. 2000;39:57-106.
71. Jablonski NG, Chaplin G. Skin deep. Sci Am. 2002;287:74-81.
72. Adams CWM. A Colour Atlas of Multiple Sclerosis & Other Myelin Disorders. Ipswich, Suffolk, UK: Wolfe Medical Publications; 1989, p. 101.
73. Kimlin MG, Olds WJ, Moore MR. Location and vitamin D synthesis: Is the hypothesis validated by geophysical data? J Photochem Photobiol B: Biology. 2007;86:234–239.
74. Cantorna MT. Vitamin D and autoimmunity: Is vitamin D status an environmental factor affecting autoimmune disease prevalence? Proc Soc Exp Biol Med. 2000;223:230-233.
75. Deluca HF, Cantorna MT. Vitamin D: Its role and uses in immunology. FASEB J. 2001;15:2579-2585.
76. Griffin MD, Lutz W, Phan VA, et al. Dendritic cell modulation by 1-alpha,25 dihydroxyvitamin D3 and its analogs: A vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci. 2001;98:6800-6805.
77. Tavera-Mendoza LE, White JH. Cell defenses and the sunshine vitamin. Sci Am. 2007;297(5):62-72. doi:10.1038/scientificamerican1107-62.
78. Cantorna MT, Mahon BD. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med. 2004;229:1136-1142.
79. Van der Mei IA, Ponsonby AL, Dwyer T, et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: Case-control study. Br Med J. 2003;327:316-322.
80. Van der Mei IA, Ponsonby AL, Dwyer T, et al. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol. 2007;254:581-90.
81. Munger KL, Levin LI, Hollis BW, et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. Am Med Assoc J. 2006;296:2832-2838.
82. Munger KL, Zhang SM, O’Reilly E, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology. 2004;62:60-65.
83. Hernán MA, Olek MJ, Ascherio A. Geographic variation of MS incidence in two prospective studies of US women. Neurology. 1999;53:1711–1718.
84. Koch-Henriksen N. The Danish Multiple Sclerosis Registry: a 50-year follow-up. Mult Scler. 1999;5:293-296.
85. Celius EG, Vandvik B. Multiple sclerosis in Oslo, Norway: prevalence on 1 January 1995 and incidence over a 25-year period. Eur J Neurol. 2001;8:463-469.
86. Barnett MH, William DB, Day S, et al. Progressive increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: a 35-year study. J Neurol Sci. 2003;213:1–6.
87. Ranzato F, Perini P, Tzintzeva E, et al. Increasing frequency of multiple sclerosis in Padova, Italy: a 30 year epidemiological survey. Mult Scler. 2003;9:387-392.
88. Sundström P, Nyström L, Forsgren L. Incidence (1988-97) and prevalence (1997) of multiple sclerosis in Västerbotten County in northern Sweden. J Neurol Neurosurg Psychiatry. 2003;74:29-32.
89. Sarasoja T, Wikström J, Paltamaa J, et al. Occurrence of multiple sclerosis in central Finland: a regional and temporal comparison during 30 years. Acta Neurol Scand. 2004;110:331-6.
90. Freedman DM, Mustafa M, and Alavanja MCR. Mortality from multiple sclerosis and exposure to residential and occupational solar radiation: A case-control study based on death certificates. Occup Environ Med. 2000;57:418–421.
91. Emmons KM, Colditz GA. Preventing excess sun exposure: It is time for a national policy. J Natl Cancer Inst. 1999;91:1269-1270.
92. Goodin DS. The causal cascade to multiple sclerosis: a model for MS pathogenesis. PLoS One. 2009;4:e4565.
93. Mumford CJ, Wood NW, Kellar-Wood H, et al. The British Isles survey of multiple sclerosis in twins. Neurology. 1994;44:11-15.
94. Nielsen NM, Westergaard T, Rostgaard K, et al. Familial risk of multiple sclerosis: A nationwide cohort study Am J Epidemiol 2005;162:774–778.
95. Kuusisto H, Kaprio J, Kinnunen E, et al. Concordance and heritability of multiple sclerosis in Finland: Study on a nationwide series of twins. Eur J Neurol. 2008;15:1106-1110.
96. Hansen T, Skytthe A, Stenager E, et al. Risk for multiple sclerosis in dizygotic and monozygotic twins. Mult Scler. 2005;11:500-503.
97. Hansen T, Skytthe A, Stenager E, et al. Concordance for multiple sclerosis in Danish twins: an update of a nationwide study. Mult Scler. 2005;11:504-510.
98. Ristori G, Cannoni S, Stazi MA, et al., and the Italian Study Group on MS in Twins. Multiple sclerosis in twins from continental Italy and Sardinia: A Nationwide Study Ann Neurol. 2006;59:27–34.
99. Goodin DS, Khankhanian P. Single Nucleotide Polymorphism (SNP)-Strings: An Alternative Method for Assessing Genetic Associations. PLoS One. 2014;9(4):e90034.
100. Goodin DS, Khankhanian P, Gourraud, PA, Vince N. Highly conserved extended haplotypes of the major histocompatibility complex and their relationship to multiple sclerosis susceptibility. PLoS One. 2018;13(2):e0190043.
101. Goodin DS, Khankhanian P, Gourraud, PA, Vince N. Genetic susceptibility to multiple sclerosis: Interactions between conserved extended haplotypes of the MHC and other susceptibility regions. (submitted).
102. Goodin DS, Khankhanian P, Gourraud, PA, Vince N. The nature of genetic and environmental susceptibility to multiple sclerosis. PLoS One. 2020;16(3): e0246157.
103. Harrison’s Principles of Internal Medicine, 18th Edition. Longo DL, Kasper, DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo JL., eds. New York, NY: McGraw Hill Medical; 2012.
104. Witte JS, Carlin JB, Hopper JL. Likelihood-based approach to estimating twin concordance for dichotomous traits. Genetic Epidemiol. 1999;16:290–304
105. Wallin MT, Culpepper WJ, Campbell JD, et al. US Multiple Sclerosis Prevalence Workgroup. The prevalence of MS in the United States: A population-based estimate using health claims data Neurology. 2019;92:e1029-e1040.
106. Harding K, Zhu F, Alotaibi MD, et al. Causes that contribute to deaths due to multiple sclerosis: analysis of population-based multiple-cause-death data. Presentation 144. ECTRIMS 2018, Berlin.
107. Jacobson HI. The maximum variance of restricted unimodal distributions. Ann Math Stat. 1969;40:1746–52.
108. Freeman JB, Dale R. Assessing bimodality to detect the presence of a dual cognitive process. Behav Res. 2013;45:83–97.
109. Fisher LD, van Belle G. Biostatistics: A Methodology for the Health Sciences,
New York, NY: John Wiley & Sons; 1993, pp. 786-829.
110. Okuda DT, Mowery EM, Cree BAC, et al. Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome. Neurology. 2011;76:686-692.
2. Vost A, Wolochow D, Howell D. Incidence of infarcts of the brain in heart diseases. J Path Bact. 1964;88:463-470.
3. Georgi VW. Multiple Sklerose: Patholiogisch-Anamtomische Befunde multiple Sklerose bei klinisch nicht diagniostizierte Krankbeiten. Schweiz Med Wochenschr. 1966;20:605-607.
4. Gilbert J, Sadler M. Unsuspected multiple sclerosis. Arch Neurol. 1983;40:533-536.
5. Engell T. A clinical patho-anatomical study of clinically silent multiple sclerosis. Acta Neurol Scand. 1989;79:428-430.
6. Gourraud PA, Harbo HF, Hauser SL, Baranzini SE. The genetics of multiple sclerosis: an up-to-date review. Immunol Rev. 2012;248:87–103.
7. Hofker MH, Fu J, Wijmenga C. The genome revolution and its role in understanding complex diseases. Biochim Biophys Acta. 2014;1842:1889-1895.
8. Goodin DS. The nature of genetic susceptibility to multiple sclerosis: Constraining the Possibilities. BMC Neurology. 2016;16:56.
9. Goodin DS. The Genetic and Environmental Bases of Complex Human-Disease: Extending the Utility of Twin-Studies. PLoS One. 2012;7(12): e47875.
10. Herrera BM, Cader MZ, Dyment DA, et al. Multiple sclerosis susceptibility and the X chromosome. Mult Scler. 2007;13:856–8.
11. Baranzini SE, Wang J, Gibson RA, et al. Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. Hum Mol Genet. 2009;18:767-778.
12. Sanna, S. Pitzalis M, Zoledziewska M, et al. Variants within the immunoregulatory CBLB gene are associated with multiple sclerosis. Nature Genet. 2010;42:495–497.
13. The International Multiple Sclerosis Genetics Consortium & the Wellcome Trust Case Control Consortium. Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature. 2011;476:214-219.
14. International Multiple Sclerosis Genetics Consortium (IMSGC). Analysis of immune-related loci identifies 48 new susceptibility variants for multiple sclerosis Nat Genet. 2014;45:1353-60.
15. International Multiple Sclerosis Genetics Consortium. Multiple sclerosis genomic map
implicates peripheral immune cells and microglia in susceptibility. Science. 2019;365 (6460). doi:10.1126/science.aav7188.
16. Dyment DA, Herrera BM, Cader Z, et al. Complex interactions among MHC haplotypes in multiple sclerosis: susceptibility and resistance. Hum Mol Genet 2005;14:2019-2026.
17. Ramagopalan, SV, Anderson, C, Sadovnick, AD, Ebers, GC. Genomewide study of multiple sclerosis. N. Engl. J. Med. 2007;357, 2199–2200.
18. Link J, Kockum I, Lorentzen AR, et al. Importance of Human Leukocyte Antigen (HLA) Class I and II Alleles on the Risk of Multiple Sclerosis. PLoS One. 2012;7(5):e36779.
19. Patsopoulos NA, Barcellos LF, Hintzen RQ, et al. Fine-Mapping the Genetic Association of the Major Histocompatibility Complex in Multiple Sclerosis: HLA and Non-HLA Effects. PLoS Genet. 2014;9(11):e1003926.
20. Chao MJ, Barnardo MC, Lincoln MR, et al. HLA class I alleles tag HLA-DRB1*1501 haplotypes for differential risk in multiple sclerosis susceptibility. Proc Natl Acad Sci USA. 2008;105:13069-74.
21. Lincoln MR, Ramagopalan SV, Chao MJ, et al. Epistasis among HLA-DRB1, HLA-DQA1, and HLA-DQB1 loci determines multiple sclerosis susceptibility. Proc Natl Acad Sci USA. 2009;106:7542-7.
22. Sadovnick AD, Ebers GC, Dyment DA, et al., and the Canadian Collaborative Study Group. Evidence for genetic basis of multiple sclerosis. Lancet 1996;347:1728-1730.
23. Ebers GC, Yee IML, Sandovnick AD, Duquette P, and the Canadian Collaborative Study Group. Conjugal multiple sclerosis: Population-based prevalence and recurrence risks in offspring. Ann Neurol. 2000;48:927-931.
24. Willer CJ, Dyment DA, Risch NJ, Sadovnick AD, Ebers GC, the Canadian Collaborative Study Group. Twin concordance and sibling recurrence rates in multiple sclerosis. Proc Natl Acad Sci U S A. 2003;100:12877–82.
25. Dyment DA, Yee IML, Ebers GC, SadovnickAD, and the Canadian Collaborative Study Group. Multiple sclerosis in stepsiblings: Recurrence risk and ascertainment. J Neurol Neurosurg Psychiatry. 2006;77:258–259.
26. Orton SM, Herrera BM, Yee IM, et al., and the Canadian Collaborative Study Group. Sex ratio of multiple sclerosis in Canada: A longitudinal study. Lancet Neurol. 2006;5:932–6.
27. Sadovnick AD, Yee IML, Ebers GC, and the Canadian Collaborative Study Group. Multiple sclerosis and birth order: A longitudinal cohort study. Lancet Neurol. 2005;4:611–617.
28. Ebers GC, Sadovnick AD, Dyment DA, et al. Parent-of-origin effect in multiple sclerosis: observations in half-siblings. Lancet. 2004;363: 1773–1774.
29. Bager P, Nielsen NM, Bihrmann K, et al. Sibship characteristics and risk of multiple sclerosis: A nationwide cohort study in Denmark. Am J Epidemiol. 2006;163:1112–1117.
30. Kantarci OH, Barcellos LF, Atkinson EJ, et al. Men transmit MS more often to their children vs women: The Carter effect Neurology. 2006;67:305–310
31. Herrera BM, Ramagopalan SV, Orton S, et al. Parental transmission of MS in a population-based Canadian cohort. Neurology. 2007;69:1208–1212.
32. Islam T, Gauderman WJ, Cozen W, et al. Differential twin concordance for multiple sclerosis by latitude of birthplace Ann Neurol. 2006;60:56–64.
33. Robertson NP, Fraser M, Deans J, et al. Age-adjusted recurrence risks for relatives of patients with multiple sclerosis. Brain. 1996;119, 449-455.
34. Compston A, Coles A. Multiple sclerosis. Lancet. 2002;359:1221-31.
35. Willer CJ, Dyment DA, Sadovnick AD, et al. Timing of birth and risk of multiple sclerosis: population based study. Br Med J. 2005;330:120-124.
36. Templer DI, Trent NH, Spencer DA, et al. Season of birth in multiple sclerosis. Acta Neurol Scand. 1992;85:107-109.
37. Staples J, Ponsonby AL, Lim L. Low maternal exposure to ultraviolet radiation in pregnancy, month of birth and risk of multiple sclerosis in offspring: a longitudinal analysis. Br Med J. 2010;340:c1640.
38. Torkildsen Ø, Aarseth J, Benjaminsen E, et al. Month of birth and risk of multiple sclerosis: confounding and adjustments. Ann Clin Transl Neurol. 2014;1:141–144.
39. Pantavou KG, Bagos PG. Season of birth and multiple sclerosis: a systematic review and multivariate meta‑analysis J Neurol. 2020;267:2815–2822.
40. Fiddes B, Wason J, Kemppinen A, et al. Confounding underlies the apparent month of birth effect in multiple sclerosis. Ann Neurol. 2013;73:714-270.
41. Fiddes B, Wason J, Sawcer S. Confounding in association studies: month of birth and multiple sclerosis J Neurol. 2014;261:1851-1856.
42. Dean G, Kurtzke JF. On the risk of multiple sclerosis according to age at immigration to South Africa. Br Med J. 1971;3:725-729.
43. Alter M, Kahana E, Loewenson R. Migration and risk of multiple sclerosis. Neurology. 1978;28:1089-1093.
44. Elian M, Nightingale S, Dean G. Multiple sclerosis among United Kingdom-born children of immigrants from the Indian subcontinent, Africa, and the West Indies. J Neurol Neurosurg Psychiatr. 1960;53:906-911.
45. Kahana E, Zilber N, Abramson JH, et al. Multiple sclerosis: Genetic versus environmental aetiology: Epidemiology in Israel updated. J Neurol. 1994;241:341-346.81
46. Cabre P. Signate A. Olindo S, et al. Role of return migration in the emergence of multiple sclerosis in the French West Indies Brain. 2005;128:2899–2910.
47. Compston A, Confavreux C, Lassmann H, et al., eds. McAlpine’s Multiple Sclerosis, 4th ed. London, UK: Churchill Livingston; 2006
48. Sumaya CV, Myers LW, Ellison GW. Epstein-Barr virus antibodies in multiple sclerosis. Arch Neurol. 1980;37:94–96.
49. Sumaya CV, Myers LW, Ellison GW, et al. Increased prevalence and titer of Epstein-Barr virus antibodies in patients with multiple sclerosis. Ann Neurol. 1985;17:371–377.
50. Ascherio A, Munger KL, Lennette ET, et al. Epstein-Barr virus antibodies and the risk of multiple sclerosis: A prospective study. Am Med Assoc J. 2001;286:3083-3088.
51. Goldacre MJ, Wotton CJ, Seagroatt V, et al. Multiple sclerosis after infectious mononucleosis: record linkage study. J Epidemiol Community Health. 2004;58:1032-1035.
52. Sundström P, Juto G, Wadell G, et al. An altered immune response to Epstein-Barr virus in multiple sclerosis: A prospective study. Neurology. 2004;62;2277-2282.
53. Haahr S, Plesner AM, Vestergaard BF, et al. A role of late Epstein-Barr virus infection in multiple sclerosis. Acta Neurol Scand. 2004;109: 270–275.
54. Ponsonby AL, van der Mei, Dwyer T, et al. Exposure to infant siblings during early life and risk of multiple sclerosis. Am Med Assoc J. 2005;293:463-9.
55. Farrell PJ. Role for HLA in susceptibility to infectious mononucleosis. J Clin Invest. 2007;117:2756-2758.
56. Nielsen TR, Rostgaard K, Nielsen NM, et al. Multiple sclerosis after infectious mononucleosis. Arch Neurol. 2007;64:72-75.
57. Serafini B, Roiscarelli B, Franciotta D, et al. Dysregulated Epstein-Barr virus infection in multiple sclerosis. J Exp Med. 2007;204:2899-2912.
58. Ascherio A, Munger KL. Epidemiology of Multiple Sclerosis: From Risk Factors to Prevention—An Update. Semin Neurol. 2016;36:103-114.
59. Abrahamyan S, Eberspächer B, Hoshi MM, et al. Complete Epstein-Barr virus seropositivity in a large cohort of patients with early multiple sclerosis J Neurol Neurosurg Psychiatry. 2020;91:681-686.
60. Henle W, Henle G, Andersson J, et al. Antibody responses to Epstein-Barr virus-determined nuclear antigen (EBNA)-1 and EBNA-2 in acute and chronic Epstein-Barr virus infection. Proc Natl Acad Sci (USA). 1987;84:570-574.
61. Holick MF. Vitamin D requirements for humans of all ages: new increased requirements for women and men 50 years and older. Osteoporos Int. 1998;8(Suppl 2):S24-29.
62. Hayes CE, Nashold FE Spach KM, et al. The immunological functions of the vitamin D endocrine system. Cell Molec Biol. 2003;49:277-300.
63. Nagpal S, Na S, Rathnachalam R. Noncalcemic actions of vitamin D receptor ligands. Endocr Rev. 2005;26:662-687.
64. Lips P. Vitamin D physiology. Prog Biophys Molec Biol. 2006;92:4-8.
65. Sinclair H. Polyunsaturated fatty acids in multiple sclerosis. Br Med J. 1977;2:1217.
66. Koch-Henderson N. Multiple sclerosis in Scandinavia and Finland. Acta Neurol Scand. 1995;161:55-59.
67. Grønlie SA, Myrvoll E, Hansen G, et al. Multiple sclerosis in North Norway, and first appearance in an indigenous population. J Neurol. 2000;247:129–133.
68. Gillie O. A new government policy is needed for sunlight and vitamin D. Br J Dermatol. 2006;154:1052–1061.
69. Ramagopalan SV, Maugeri NJ, Handunnetthi L, et al. Expression of the multiple sclerosis-associated MHC class II Allele HLA-DRB1*1501 is regulated by vitamin D. PLoS Genet. 2009;5(2):e1000369
70. Jablonski NG, Chaplin G. The evolution of human skin coloration. J Hum Evol. 2000;39:57-106.
71. Jablonski NG, Chaplin G. Skin deep. Sci Am. 2002;287:74-81.
72. Adams CWM. A Colour Atlas of Multiple Sclerosis & Other Myelin Disorders. Ipswich, Suffolk, UK: Wolfe Medical Publications; 1989, p. 101.
73. Kimlin MG, Olds WJ, Moore MR. Location and vitamin D synthesis: Is the hypothesis validated by geophysical data? J Photochem Photobiol B: Biology. 2007;86:234–239.
74. Cantorna MT. Vitamin D and autoimmunity: Is vitamin D status an environmental factor affecting autoimmune disease prevalence? Proc Soc Exp Biol Med. 2000;223:230-233.
75. Deluca HF, Cantorna MT. Vitamin D: Its role and uses in immunology. FASEB J. 2001;15:2579-2585.
76. Griffin MD, Lutz W, Phan VA, et al. Dendritic cell modulation by 1-alpha,25 dihydroxyvitamin D3 and its analogs: A vitamin D receptor-dependent pathway that promotes a persistent state of immaturity in vitro and in vivo. Proc Natl Acad Sci. 2001;98:6800-6805.
77. Tavera-Mendoza LE, White JH. Cell defenses and the sunshine vitamin. Sci Am. 2007;297(5):62-72. doi:10.1038/scientificamerican1107-62.
78. Cantorna MT, Mahon BD. Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med. 2004;229:1136-1142.
79. Van der Mei IA, Ponsonby AL, Dwyer T, et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis: Case-control study. Br Med J. 2003;327:316-322.
80. Van der Mei IA, Ponsonby AL, Dwyer T, et al. Vitamin D levels in people with multiple sclerosis and community controls in Tasmania, Australia. J Neurol. 2007;254:581-90.
81. Munger KL, Levin LI, Hollis BW, et al. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. Am Med Assoc J. 2006;296:2832-2838.
82. Munger KL, Zhang SM, O’Reilly E, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology. 2004;62:60-65.
83. Hernán MA, Olek MJ, Ascherio A. Geographic variation of MS incidence in two prospective studies of US women. Neurology. 1999;53:1711–1718.
84. Koch-Henriksen N. The Danish Multiple Sclerosis Registry: a 50-year follow-up. Mult Scler. 1999;5:293-296.
85. Celius EG, Vandvik B. Multiple sclerosis in Oslo, Norway: prevalence on 1 January 1995 and incidence over a 25-year period. Eur J Neurol. 2001;8:463-469.
86. Barnett MH, William DB, Day S, et al. Progressive increase in incidence and prevalence of multiple sclerosis in Newcastle, Australia: a 35-year study. J Neurol Sci. 2003;213:1–6.
87. Ranzato F, Perini P, Tzintzeva E, et al. Increasing frequency of multiple sclerosis in Padova, Italy: a 30 year epidemiological survey. Mult Scler. 2003;9:387-392.
88. Sundström P, Nyström L, Forsgren L. Incidence (1988-97) and prevalence (1997) of multiple sclerosis in Västerbotten County in northern Sweden. J Neurol Neurosurg Psychiatry. 2003;74:29-32.
89. Sarasoja T, Wikström J, Paltamaa J, et al. Occurrence of multiple sclerosis in central Finland: a regional and temporal comparison during 30 years. Acta Neurol Scand. 2004;110:331-6.
90. Freedman DM, Mustafa M, and Alavanja MCR. Mortality from multiple sclerosis and exposure to residential and occupational solar radiation: A case-control study based on death certificates. Occup Environ Med. 2000;57:418–421.
91. Emmons KM, Colditz GA. Preventing excess sun exposure: It is time for a national policy. J Natl Cancer Inst. 1999;91:1269-1270.
92. Goodin DS. The causal cascade to multiple sclerosis: a model for MS pathogenesis. PLoS One. 2009;4:e4565.
93. Mumford CJ, Wood NW, Kellar-Wood H, et al. The British Isles survey of multiple sclerosis in twins. Neurology. 1994;44:11-15.
94. Nielsen NM, Westergaard T, Rostgaard K, et al. Familial risk of multiple sclerosis: A nationwide cohort study Am J Epidemiol 2005;162:774–778.
95. Kuusisto H, Kaprio J, Kinnunen E, et al. Concordance and heritability of multiple sclerosis in Finland: Study on a nationwide series of twins. Eur J Neurol. 2008;15:1106-1110.
96. Hansen T, Skytthe A, Stenager E, et al. Risk for multiple sclerosis in dizygotic and monozygotic twins. Mult Scler. 2005;11:500-503.
97. Hansen T, Skytthe A, Stenager E, et al. Concordance for multiple sclerosis in Danish twins: an update of a nationwide study. Mult Scler. 2005;11:504-510.
98. Ristori G, Cannoni S, Stazi MA, et al., and the Italian Study Group on MS in Twins. Multiple sclerosis in twins from continental Italy and Sardinia: A Nationwide Study Ann Neurol. 2006;59:27–34.
99. Goodin DS, Khankhanian P. Single Nucleotide Polymorphism (SNP)-Strings: An Alternative Method for Assessing Genetic Associations. PLoS One. 2014;9(4):e90034.
100. Goodin DS, Khankhanian P, Gourraud, PA, Vince N. Highly conserved extended haplotypes of the major histocompatibility complex and their relationship to multiple sclerosis susceptibility. PLoS One. 2018;13(2):e0190043.
101. Goodin DS, Khankhanian P, Gourraud, PA, Vince N. Genetic susceptibility to multiple sclerosis: Interactions between conserved extended haplotypes of the MHC and other susceptibility regions. (submitted).
102. Goodin DS, Khankhanian P, Gourraud, PA, Vince N. The nature of genetic and environmental susceptibility to multiple sclerosis. PLoS One. 2020;16(3): e0246157.
103. Harrison’s Principles of Internal Medicine, 18th Edition. Longo DL, Kasper, DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo JL., eds. New York, NY: McGraw Hill Medical; 2012.
104. Witte JS, Carlin JB, Hopper JL. Likelihood-based approach to estimating twin concordance for dichotomous traits. Genetic Epidemiol. 1999;16:290–304
105. Wallin MT, Culpepper WJ, Campbell JD, et al. US Multiple Sclerosis Prevalence Workgroup. The prevalence of MS in the United States: A population-based estimate using health claims data Neurology. 2019;92:e1029-e1040.
106. Harding K, Zhu F, Alotaibi MD, et al. Causes that contribute to deaths due to multiple sclerosis: analysis of population-based multiple-cause-death data. Presentation 144. ECTRIMS 2018, Berlin.
107. Jacobson HI. The maximum variance of restricted unimodal distributions. Ann Math Stat. 1969;40:1746–52.
108. Freeman JB, Dale R. Assessing bimodality to detect the presence of a dual cognitive process. Behav Res. 2013;45:83–97.
109. Fisher LD, van Belle G. Biostatistics: A Methodology for the Health Sciences,
New York, NY: John Wiley & Sons; 1993, pp. 786-829.
110. Okuda DT, Mowery EM, Cree BAC, et al. Asymptomatic spinal cord lesions predict disease progression in radiologically isolated syndrome. Neurology. 2011;76:686-692.